← Back to Search

Cytokine

CSF-1 for Presbyopia

Phase 3
Waitlist Available
Research Sponsored by Orasis Pharmaceuticals Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Subjects must have presbyopia
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing the safety of a new treatment called CSF-1 for people who have trouble seeing things up close due to aging. The study will compare CSF-1 to another treatment over a period of time.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2022 Phase 3 trial • 309 Patients • NCT04599933
6%
instillation site pain
5%
headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
CSF-1
Vehicle

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CSF-1Experimental Treatment1 Intervention
One drop bilaterally twice daily for approximately 6 weeks
Group II: VehiclePlacebo Group1 Intervention
One drop bilaterally twice daily for approximately 6 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CSF-1
2022
Completed Phase 3
~960

Find a Location

Who is running the clinical trial?

Orasis Pharmaceuticals Ltd.Lead Sponsor
5 Previous Clinical Trials
851 Total Patients Enrolled
5 Trials studying Presbyopia
851 Patients Enrolled for Presbyopia
~53 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top